Biomarin Pharmaceutical Inc. (BMRN)
BioMarin Pharmaceutical's Rare Disease Portfolio Supplemented By Amicus Acquisition Makes A Buy
BioMarin (BMRN) has declined over 12% since January 2025, despite prior optimism. The investment thesis centers on the potential of VOXZOGO and Amicus's two approved therapies to drive future upside. Current share weakness may present a buying opportunity given VOXZOGO's prospects.
BioMarin (BMRN) Down 13.6% Since Last Earnings Report: Can It Rebound?
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?
BioMarin stops mid-stage trials of bone disorder treatment
BioMarin Pharmaceutical will discontinue mid-stage trials of its bone disorder treatment after reports of several cases of patients' hip joint slipping out of place, the drugmaker said on Monday, sending its shares down 4%.
BioMarin Pharmaceutical Inc. (BMRN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
BioMarin Pharmaceutical Inc. (BMRN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
BioMarin Pharmaceutical Inc. (BMRN) Presents at Leerink Global Healthcare Conference 2026 Transcript
BioMarin Pharmaceutical Inc. (BMRN) Presents at Leerink Global Healthcare Conference 2026 Transcript
BioMarin Pharmaceutical Inc. (BMRN) Presents at TD Cowen 46th Annual Health Care Conference Transcript
BioMarin Pharmaceutical Inc. (BMRN) Presents at TD Cowen 46th Annual Health Care Conference Transcript
BMRN Beats on Q4 Earnings, to Withdraw Roctavian From Market
BioMarin beats Q4 earnings estimates as Voxzogo drives year-over-year revenue growth. The company decides to voluntarily withdraw its hemophilia gene therapy.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
BioMarin Pharmaceutical Inc. (BMRN) Q4 2025 Earnings Call Transcript
BioMarin Pharmaceutical Inc. (BMRN) Q4 2025 Earnings Call Transcript
Compared to Estimates, BioMarin (BMRN) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for BioMarin (BMRN) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
BioMarin Pharmaceutical (BMRN) Beats Q4 Earnings and Revenue Estimates
BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.92 per share a year ago.
Countdown to BioMarin (BMRN) Q4 Earnings: Wall Street Forecasts for Key Metrics
Besides Wall Street's top-and-bottom-line estimates for BioMarin (BMRN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
